BioCryst Pharmaceuticals (BCRX) to Release Quarterly Earnings on Thursday


Share on StockTwits

BioCryst Pharmaceuticals (NASDAQ:BCRX) will be releasing its earnings data before the market opens on Thursday, May 6th. Analysts expect BioCryst Pharmaceuticals to post earnings of ($0.26) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, February 24th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.09). BioCryst Pharmaceuticals had a negative return on equity of 328.70% and a negative net margin of 233.45%. The company had revenue of $4.02 million for the quarter, compared to analyst estimates of $14.72 million. On average, analysts expect BioCryst Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ BCRX opened at $11.18 on Tuesday. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -14.71 and a beta of 3.03. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.45 and a quick ratio of 1.40. BioCryst Pharmaceuticals has a 12 month low of $3.30 and a 12 month high of $14.24. The company’s fifty day moving average price is $11.24 and its two-hundred day moving average price is $8.48.

BCRX has been the subject of several research analyst reports. Cowen started coverage on BioCryst Pharmaceuticals in a report on Monday, March 1st. They issued an “outperform” rating and a $16.00 price objective for the company. HC Wainwright lifted their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday, March 30th. Zacks Investment Research raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 15th. TheStreet lowered shares of BioCryst Pharmaceuticals from a “c-” rating to a “d-” rating in a report on Thursday, February 25th. Finally, JPMorgan Chase & Co. raised their target price on shares of BioCryst Pharmaceuticals from $10.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, March 17th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $11.55.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company, which engages in the development and discovery of novel, oral, and small-molecule medicines. It focuses on the oral treatments for rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease.

See Also: Penny Stocks, Risk and Reward Factors

Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.